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Discussion
Dr Arvind Koshal (Edmonton, Alberta, Canada). Thank you very
much, Dr David, for an excellent presentation. This is an excellent
example to all of us of how you took a product from the initial
development stage, brought it into the market, and are now pro-
viding us with 100% follow-up on these 357 patients. You should
be congratulated for doing that and giving us a lot of information.
It is interesting that the survival has been good despite a
durability issue that we have seen with tissue valves in the past.
The difference, though, in using stented valves with poor durabil-
ity was that at the time of reoperation, the reoperation was not that
technically complicated. What were the technical problems on
reoperation in these patients who have a more complex way of
insertion and also where coronary ostia and sinuses are involved?
What kind of valve or conduit do you use at that stage?
Dr David. The experience is largely personal. We have oper-
ated on 50 patients, and 28 required aortic root replacement be-
cause in attempting to remove the valve we damaged the aortic
sinuses and/or aortic arch annulus. The operative mortality for
elective reoperation for failed stentless valves is twice as high as
for bioprostheses.
Dr Koshal. What kind of valve did you use at the second
operation?
Dr David. Surprisingly, most patients wanted a bioprosthesis
again.
Dr Koshal. The other interesting thing in your series is that you
have a significant percentage of bicuspid aortic valves. As you
know, with bicuspid valves the aorta is more prone to degenerative
changes. Did you find a difference in the durability in the bicuspid
versus the tricuspid valves that were replaced?
Dr David. That is an important question. Patients with bicuspid
aortic valves eventually had aortic dilation, and because this valve
function is dependent on the aortic root, if the aorta dilates the
valve becomes incompetent. This was the case, unfortunately, but
bicuspid aortic valve was not a predictor of late failure. Dilatation
of the aorta was. Unfortunately, the literature suggests that the
aorta dilates as we age. In the age group of 50 to 80 years, if the
aorta increases from 25 to 30 mm in diameter to 35 mm or so, this
valve is rendered incompetent. I learned this only in 1998 and I
started banding it, but we do not have long enough follow-up on
those patients. Clearly, dilatation of the aorta was the most com-
mon mode of failure in these patients.
Dr Koshal. Finally, what are you going to do with this valve
now? How many of these do you use in your practice and what
have you changed to?
Dr David. I continue using it but I do not use it in younger
patients anymore. The enthusiasm was so great 18 years ago when
it was first developed. We thought it was going to take over the use
of homografts because it is relatively easy to implant and I thought
it was going to be more durable. We limit it to older patients, over
65 or 70 years. In those, failure is uncommon. Hemodynamically,
it is an outstanding valve.
Dr John Brown (Indianapolis, Ind). Do you have any com-
parison of the Toronto valve with the other stentless valves on the
market to see whether they are showing the same problems that the
Toronto valve has?
Dr David. We do, Dr Brown. We have followed up most
patients who had valve surgery with biological and bioprosthetic
valves. Compared with the Hancock II, this valve is not as durable,
not by much though. At 10 years there is a 10% difference and at
12 years a 12% difference for all comers. However, the survival at
12 years is 20% better for the stentless valve. I am not saying that
if I need an AVR, I am going to have a stentless valve because I
am likely to live longer than the durability of this valve. The
beneficial effect of better hemodynamics likely is not apparent in
the first year or two. It might take a decade or more to become
apparent. I firmly believe that if a patient comes for AVR, the
surgeon should resolve the hemodynamic burden that the native
aortic valve disease caused. This valve is very close to it in elderly
patients, and that is why I continue using Ross in younger patients.
I think it is an outstanding operation in properly selected patients.
It restores the outflow tract to normality.
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